ライフサイエンスコーパス: endomyocardial biopsy

1 Nine patients underwent endomyocardial biopsy.

2 and serial echocardiography; five underwent endomyocardial biopsy.

3 gs in the diagnosis of amyloidosis proven by endomyocardial biopsy.

4 assessed by the rejection grade on the first endomyocardial biopsy.

5 osis on the basis of clinical evaluation and endomyocardial biopsy.

6 of MMF trough level at the time of scheduled endomyocardial biopsy.

7 c transplants revolves around the use of the endomyocardial biopsy.

8 DSE at the time of their regularly scheduled endomyocardial biopsy.

9 ransplantation (ISHLT) grade 2R or higher at endomyocardial biopsy.

10 nical signs and symptoms and low accuracy of endomyocardial biopsy.

11 ic work-up, including genetic evaluation and endomyocardial biopsy.

12 lantation at the time of serial surveillance endomyocardial biopsy.

13 ditis was defined by ongoing inflammation on endomyocardial biopsy.

14 Twenty-eight (88%) patients underwent endomyocardial biopsy.

15 ars) had undergone diagnostic cardiac MR and endomyocardial biopsy.

16 mic myocardial (18)F-NOS PET/CT, followed by endomyocardial biopsy.

17 nd immunoglobulins) and microvasculopathy in endomyocardial biopsy.

18 cally, the diagnosis of myocarditis required endomyocardial biopsy.

19 en shown to correlate with the results of an endomyocardial biopsy.

20 the standard method of tissue histology from endomyocardial biopsy.

21 Egr-1 mRNA expression and rejection grade in endomyocardial biopsies.

22 men was used, and rejection was monitored by endomyocardial biopsies.

23 nd arteriolar endothelial ICAM-1 in matching endomyocardial biopsies.

24 were measured in 186 patients undergoing 365 endomyocardial biopsies.

25 ents could obviate the need for surveillance endomyocardial biopsies.

26 in human atrial tissue and right ventricular endomyocardial biopsies.

27 patients who were monitored with the use of endomyocardial biopsies (0.5 vs. 3.0, P<0.001).

28 After a low-grade endomyocardial biopsy (0 or 1A), one or more donor-recip

29 hs, 64% occurred within 3 months of the last endomyocardial biopsy, 96% had normal biopsies, and the

30 ation relies on histopathological grading of endomyocardial biopsies according to International Socie

31 ter nucleic acids had been extracted from an endomyocardial biopsy, an explant, or autopsy samples, P

32 Endomyocardial biopsies and blood samples from 38 patien

33 METHODS AND Endomyocardial biopsies and blood samples were obtained

34 We reviewed the simultaneously obtained endomyocardial biopsies and intravascular ultrasound (IV

35 We evaluated PIMI in the first four weekly endomyocardial biopsies and/or autopsy myocardium from 1

36 retrospectively identified who had undergone endomyocardial biopsy and cardiac MR at one institution

37 d clinically suspected myocarditis underwent endomyocardial biopsy and CMR at 1.5 Tesla.

38 Acute allograft rejection was diagnosed by endomyocardial biopsy and graded according to the Intern

39 disorder has led to the possible overuse of endomyocardial biopsy and immunosuppressive agents.

40 transplant recipients underwent simultaneous endomyocardial biopsy and intravascular ultrasound (IVUS

41 nts require more invasive procedures such as endomyocardial biopsy and may aid in reducing the number

42 ave myocarditis according to the findings on endomyocardial biopsy and the Dallas histopathological c

43 Rejection was diagnosed using endomyocardial biopsy and were graded according to stand

44 ant recipients who were referred for routine endomyocardial biopsy and/or surveillance coronary angio

45 with histologically proven amyloid (374 with endomyocardial biopsies) and 360 patients subsequently c

46 ranscriptional profiling was performed on 26 endomyocardial biopsies, and expression patterns were co

47 Annual coronary angiograms, serial endomyocardial biopsies, and serum cardiac troponin-T co

48 echocardiogram, right ventricular angiogram, endomyocardial biopsy, and 24-hour ambulatory ECG.

49 Repeat endomyocardial biopsies are frequently needed to diagnos

50 the major limitations, and currently, serial endomyocardial biopsies are required to diagnose rejecti

51 itivity or specificity needed to replace the endomyocardial biopsy as a diagnostic tool.

52 jection in humans might obviate the need for endomyocardial biopsy as well as improve the accuracy of

53 VEGF is expressed in normal human endomyocardial biopsies at low levels and is induced (sc

54 including TD imaging, along with transmural endomyocardial biopsy at the time of coronary bypass sur

55 sis of 196 consecutive patients referred for endomyocardial biopsy because of clinical suspicion of c

56 All underwent an endomyocardial biopsy before randomization, which reveal

57 We analyzed 169 sequential human endomyocardial biopsies by immunocytochemistry for infil

58 Endomyocardial biopsy can demonstrate fibro-fatty replac

59 In some patients, cardiac MRI and endomyocardial biopsy can help identify myocarditis, pre

60 that transcriptomic biomarkers from a single endomyocardial biopsy can improve the clinical detection

61 nological factors at the time of a low-grade endomyocardial biopsy can predict progression to high-gr

62 were also found to be clonally explanted in endomyocardial biopsies collected 17 and 21 mo earlier f

63 cular atheroma excised at endarterectomy and endomyocardial biopsies contained purely variant fibrino

64 schemic changes in early posttransplantation endomyocardial biopsies correlate with the later develop

65 criptomic signature, generated from a single endomyocardial biopsy, could serve as a novel prognostic

66 Among 74 patients with endomyocardial biopsy diagnosis of FD cardiomyopathy, 13

67 transplant recipients following inadvertent endomyocardial biopsy disruption of the tricuspid appara

68 GF) mRNA expression was determined in serial endomyocardial biopsies during the first year after tran

69 -CD68) and histopathologic criteria found on endomyocardial biopsies (EMB).

70 Endomyocardial biopsy (EMB) has a low sensitivity.

71 diac magnetic resonance (CMR) mapping versus endomyocardial biopsy (EMB) has not been determined.

72 d many to question the yield of surveillance endomyocardial biopsy (EMB) in heart transplantation (HT

73 Endomyocardial biopsy (EMB) is a low risk procedure in a

74 The endomyocardial biopsy (EMB) is considered the gold stand

75 Endomyocardial biopsy (EMB) is often considered when the

76 ue of the distinction between CS and IGCM on endomyocardial biopsy (EMB) is unknown.

77 tic resonance (CMR), cardiac biomarkers, and endomyocardial biopsy (EMB) results to predict left vent

78 Use of left ventricular (LV) endomyocardial biopsy (EMB) to investigate cardiomyopath

79 tients who had blood samples obtained during endomyocardial biopsy (EMB).

80 on after heart transplant (HT), surveillance endomyocardial biopsies (EMBs) are often continued for y

81 To determine the utility of surveillance endomyocardial biopsies (EMBs) during a 14-day OKT3 indu

82 e total Treg population, we examined Treg in endomyocardial biopsies (EMBs) of both patients who deve

83 d for the presence of viral genome in serial endomyocardial biopsies (EMBs) using polymerase chain re

84 nological factors at the time of a low-grade endomyocardial biopsy enables prospective stratification

85 ited utilization and the poor sensitivity of endomyocardial biopsies (especially for patchy diseases

86 Myocardial tissue from endomyocardial biopsy, explant, or autopsy was analyzed

87 Endomyocardial biopsy fibrosis was quantitatively measur

88 Endomyocardial biopsies from 19 old patients with a dila

89 ir receptors CXCR3 and CCR5 was tested in 60 endomyocardial biopsies from 24 patients using quantitat

90 Right ventricular endomyocardial biopsies from 30 cases of allograft rejec

91 ern of vascular cardiac allograft rejection, endomyocardial biopsies from 344 heart transplant recipi

92 D We analyzed pretreatment and posttreatment endomyocardial biopsies from 58 Fabry patients enrolled

93 Autopsy specimens from 5 patients and endomyocardial biopsies from 7 patients were used for th

94 estigated in both cultured keratinocytes and endomyocardial biopsies from affected individuals.

95 the presence of acute cellular rejection in endomyocardial biopsies from cardiac transplant recipien

96 ve RT-PCR in RNA from right ventricular (RV) endomyocardial biopsies from intact nonfailing hearts, a

97 properties of mCSCs and vCSCs isolated from endomyocardial biopsies from patients with advanced hear

98 d (P=0.012) and 5.1-fold (P=0.038) higher in endomyocardial biopsies from patients with CVB3-positive

99 ntiated adult heart muscle cells, studies in endomyocardial biopsies from patients with dilated and i

100 luorescence, and immunoperoxidase studies of endomyocardial biopsies from such patients often reveal

101 echocardiograms, hemodynamic parameters, and endomyocardial biopsys from 137 patients with heart tran

102 Percentage of endomyocardial biopsies (grade 3a, 3b, and 4) with respe

103 For endomyocardial-biopsy grades 1B or 2, a positive lymphoc

104 Endomyocardial biopsy has defined rejection in clinical

105 The endomyocardial biopsy has defined the diagnosis of rejec

106 The endomyocardial biopsy has long been the preferred techni

107 Endomyocardial biopsy has stood the test of time as a su

108 nce of significant rejection on the basis of endomyocardial biopsy histology.

109 erum samples were retrospectively matched to endomyocardial biopsies in 98 cardiac transplant recipie

110 Protocol endomyocardial biopsies in all three patients revealed n

111 ed recently as potential substitutes for the endomyocardial biopsy in detecting rejection.

112 nvasive test holds promise for replacing the endomyocardial biopsy in heart transplant recipients and

113 9 (terminal pathway), at the time of routine endomyocardial biopsy in heart transplant recipients.

114 This article reviews the current role of the endomyocardial biopsy in the management of patients foll

115 ression profiling or with the use of routine endomyocardial biopsies, in addition to clinical and ech

116 ve addressed important issues concerning the endomyocardial biopsy, including the reliability of the

117 The sensitivity of transvenous endomyocardial biopsy increased from 68% (19/28 patients

118 e DNA from the donor genome at times when an endomyocardial biopsy independently established the pres

119 +) T cells and the CXCR3 ligand IP-10 within endomyocardial biopsies is strongly associated with acut

120 Percutaneous endomyocardial biopsy is a widely used and valuable proc

121 The endomyocardial biopsy is also limited by sub-optimal int

122 Endomyocardial biopsy is currently the standard method u

123 Risk of endomyocardial biopsy is highest in sick children with s

124 Endomyocardial biopsy is the major method for detecting

125 Endomyocardial biopsy is the standard method of monitori

126 Endomyocardial biopsy is used routinely for diagnosing a

127 Endomyocardial biopsy, lymphocyte-growth assays, and ant

128 in pathologic processes, Egr-1 expression in endomyocardial biopsies may act as a surrogate marker of

129 The sensitivity of endomyocardial biopsy may be increased, especially in su

130 rranted to characterize patients with TCM by endomyocardial biopsy more clearly.

131 ig), and their receptor CXCR3 in consecutive endomyocardial biopsies (n = 133) from human cardiac all

132 Antigen expression was detected on endomyocardial biopsies (n = 50) and spleen (n = 11) by

133 ion of VEGF by immunohistochemistry in human endomyocardial biopsies (n=101) from 10 cardiac transpla

134 uring subsequent cardiac surgery (n = 3) and endomyocardial biopsy (n = 1).

135 (n = 26), coronary angiography (n = 32), and endomyocardial biopsy (n = 32).

136 rdiac tissues obtained from autopsies (n=3), endomyocardial biopsy (n=1), or cardiac transplants (n=2

137 METHODS AND Endomyocardial biopsy NOD2 mRNA expression was higher in

138 ry deposition of C4d or C3d were detected in endomyocardial biopsies of 14 of the 33 patients.

139 Egr-1 protein expression was analyzed in endomyocardial biopsies of different rejection grades by

140 PAR2 expression in endomyocardial biopsies of patients with nonischemic car

141 myocardial fibrosis has been detected in the endomyocardial biopsies of survivors.

142 ling of protein-coding genes and 754 miRs in endomyocardial biopsies of test cohorts was performed at

143 We performed endomyocardial biopsies of the RV side of the septum and

144 Nine episodes of CAVB occurred during endomyocardial biopsy or coronary angiography, and four

145 rol had antibody-mediated rejection (AMR) by endomyocardial biopsy (P<0.01).

146 There was a decrease in the use of endomyocardial biopsy (P=0.03) and an increase in the us

147 ionship between MDR1/ABCB1 polymorphisms and endomyocardial biopsy-proven rejection (EBPR) determined

148 y correlated with inflammatory cell count on endomyocardial biopsy (r=0.56; P<0.05).

149 ere-derived cells (CDCs) isolated from human endomyocardial biopsies reduce infarct size and improve

150 Results were correlated with endomyocardial biopsy rejection grades.

151 Cardiac catheterization and endomyocardial biopsy remain the "gold standard" for dia

152 Endomyocardial biopsy remains the gold standard for in v

153 etection of transplant rejection by repeated endomyocardial biopsy requires catheterization and entai

154 fraction to < or = 40%, and one because her endomyocardial biopsy result was grade 1.5.

155 The therapeutic and prognostic benefits of endomyocardial biopsy results have recently been demonst

156 Analysis of serial endomyocardial biopsies revealed that high levels of end

157 Endomyocardial biopsy revealed active myocarditis in 16

158 Endomyocardial biopsy revealed more advanced grade C and

159 in patients with new-onset HF from a single endomyocardial biopsy sample.

160 munohistochemical analysis of a conventional endomyocardial-biopsy sample appears to be a highly sens

161 Endomyocardial biopsy samples and clinical data were col

162 The current study investigated endomyocardial biopsy samples from patients with TCM and

163 Levels of TSP-1 mRNA in endomyocardial biopsy samples of human cardiac allograft

164 Immunohistochemistry of endomyocardial biopsy samples revealed altered expressio

165 entification of infiltration and fibrosis in endomyocardial biopsy samples to assess transplant rejec

166 In cases of myocarditis (n=7), endomyocardial biopsy samples were analyzed by PCR and c

167 Serial LV endomyocardial biopsy samples were obtained at each echo

168 Serial LV endomyocardial biopsy samples were obtained to measure c

169 Matching endomyocardial biopsy samples were screened immunohistoc

170 Among a total of 350 endomyocardial biopsy samples, 180 were identified as id

171 nd arterial endothelial ICAM-1 expression in endomyocardial biopsy samples.

172 ulation of SA CMCs was isolated from porcine endomyocardial biopsy samples.

173 F) were correlated with clinical outcome and endomyocardial biopsy scores.

174 diac fibrosis was assessed histologically on endomyocardial biopsy sections.

175 Endomyocardial biopsy showed mononuclear infiltrates and

176 lar rejection grading scheme for heart graft endomyocardial biopsy specimens (EMBs).

177 Standard morphological features of endomyocardial biopsy specimens do not necessarily corre

178 A total of 157 endomyocardial biopsy specimens from 26 patients with he

179 Three hundred sixteen serial endomyocardial biopsy specimens from 30 heart transplant

180 Endomyocardial biopsy specimens from 40 patients with pr

181 We studied endomyocardial biopsy specimens from 7 sex-mismatched (f

182 as is expressed on myocytes, we investigated endomyocardial biopsy specimens from cardiac transplant

183 okine and receptor gene expression in serial endomyocardial biopsy specimens from heart transplant pa

184 e-transcriptase polymerase chain reaction in endomyocardial biopsy specimens from human heart transpl

185 Serial sections of individual endomyocardial biopsy specimens from patients histologic

186 Percutaneous endomyocardial biopsy specimens grown in primary culture

187 In addition, studies of endomyocardial biopsy specimens have furthered our under

188 d percent fibrosis were determined in serial endomyocardial biopsy specimens obtained from 1 month up

189 Immunocytochemistry was performed on serial endomyocardial biopsy specimens to evaluate endothelial

190 Endomyocardial biopsy specimens were evaluated during th

191 to receive CDCs, autologous cells grown from endomyocardial biopsy specimens were infused into the in

192 ologous CDCs (12.5 to 25 x 10(6)) grown from endomyocardial biopsy specimens were infused via the int

193 B19V DNA and messenger RNA from endomyocardial biopsy specimens, bone marrow specimens,

194 expression was increased during rejection in endomyocardial biopsy specimens.

195 the isolation of adult human stem cells from endomyocardial biopsy specimens.

196 Endomyocardial-biopsy specimens were evaluated for evide

197 +/- standard deviation) consecutive routine endomyocardial biopsy surveillance visits during the fir

198 ere positive, concomitantly with a low-grade endomyocardial biopsy, the positive predictive value for

199 Gal-3 levels and inflammatory cell count on endomyocardial biopsy was observed in patients with iCMP

200 m each patient were examined for AECA and an endomyocardial biopsy was performed at regular intervals

201 Endomyocardial biopsy was performed in 9 of the 12 ARVD/

202 Serial cardiac monitoring, including endomyocardial biopsies, was performed.

203 A total of 240 heart transplant endomyocardial biopsies were assessed.

204 To determine whether ischemic changes in endomyocardial biopsies were associated with complement

205 A total of 132 blood specimens and endomyocardial biopsies were collected from 35 patients,

206 Endomyocardial biopsies were collected with a bioptome f

207 Serial endomyocardial biopsies were evaluated for cellular reje

208 Endomyocardial biopsies were evaluated within 2 weeks of

209 Porcine endomyocardial biopsies were harvested and plated as org

210 Autologous cardiospheres or CDCs grown from endomyocardial biopsies were injected through thoracotom

211 Serial radionuclide ventriculography and endomyocardial biopsies were performed at baseline, 3, a

212 methods for the detection of rejection, the endomyocardial biopsy will remain important in the manag

213 inical safety of any such approach, invasive endomyocardial biopsy will remain the gold standard.

214 tegory (1R) appears to have brought together endomyocardial biopsies with different underlying proces

215 eactivity was not detectable in four of five endomyocardial biopsies with normal histology.

216 ized that the transcriptome obtained from an endomyocardial biopsy would yield clinically relevant an